Search Result

Results for "

SGLT2 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Cytochrome P450 (1) Endogenous Metabolite (3) GLUT (2) HBV (1) HSV (1) Isotope-Labeled Compounds (1) Reactive Oxygen Species (1) SGLT (52)
By Research Areas:	Cancer (11) Endocrinology (1) Infection (2) Inflammation/Immunology (2) Metabolic Disease (52) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15409

Empagliflozin Maximum Cited Publications 60 Publications Verification BI 10773	SGLT	Metabolic Disease
Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-I1120

SGLT2-IN-1	SGLT	Metabolic Disease
SGLT2-IN-1 (Compound 5) is an inhibitor for sodium-dependent glucose cotransporter (SGLT2), with IC₅₀ of 33 nM .

HY-14894

Ipragliflozin 5+ Cited Publications ASP1941	SGLT	Metabolic Disease
Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-109092

Licogliflozin 1 Publications Verification LIK066	SGLT	Metabolic Disease Inflammation/Immunology
Licogliflozin is a sodium glucose cotransporter (SGLT1 and *SGLT2) inhibitor*.

HY-116223

Tianagliflozin	SGLT	Metabolic Disease
Tianagliflozin is a sodium/glucose cotransporter 2 (SGLT-2) inhibitor with potential for investigation in type 2 diabetes .

HY-122473

fluoro-Dapagliflozin	SGLT	Metabolic Disease
fluoro-Dapagliflozin, a structural analog of Dapagliflozin, is a selective *SGLT2* inhibitor with K_i values of 5.3 nM and 330 nM for SGLT2 and SGLT1, respectively. fluoro-Dapagliflozin blocks glucose transport and glucose-coupled currents .

HY-14894R

Ipragliflozin (Standard)	SGLT	Metabolic Disease
Ipragliflozin (Standard) is the analytical standard of Ipragliflozin. This product is intended for research and analytical applications. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-15409R

Empagliflozin (Standard)	SGLT	Metabolic Disease
Empagliflozin (Standard) is the analytical standard of Empagliflozin. This product is intended for research and analytical applications. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-14902

Tofogliflozin CSG452	SGLT	Metabolic Disease
Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

HY-13414

Remogliflozin Remogliflozin A	SGLT	Metabolic Disease
Remogliflozin is a potent and selective inhibitor of *SGLT2* (sodium-glucose cotransporter 2) with K_is of 12.4 and 26 nM for human and rat SGLT2, respectively. Remogliflozin is the active form of Remogliflozin etabonate(HY-14945) .

HY-123011

Henagliflozin SHR3824	SGLT	Metabolic Disease
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC₅₀ values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .

HY-15461

Ertugliflozin 2 Publications Verification PF-04971729	SGLT	Metabolic Disease
Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-15461A

Ertugliflozin L-pyroglutamic acid 2 Publications Verification PF-04971729 L-pyroglutamic acid	SGLT	Metabolic Disease
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-15516

Sotagliflozin 10+ Cited Publications LX-4211; LP-802034	SGLT	Metabolic Disease
Sotagliflozin (LX-4211) is a potent dual SGLT2/1 inhibitor. Antidiabetic agents.

HY-109018

Velagliflozin 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.

HY-10451S

Canagliflozin-d4 JNJ 28431754-d₄	SGLT	Metabolic Disease Cancer
Canagliflozin-d₄ is a deuterium labeled Canagliflozin. Canagliflozin is a selective SGLT2 inhibitor[1].

HY-10450S

Dapagliflozin-d5 BMS-512148-d₅	SGLT	Metabolic Disease Cancer
Dapagliflozin-d₅ is a deuterium labeled Dapagliflozin. Dapagliflozin is a competitive SGLT2 inhibitor[1].

HY-15409S

Empagliflozin-d4 BI 10773-d₄	SGLT	Metabolic Disease
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].

HY-138944

SGLT1/2-IN-1	SGLT	Metabolic Disease
SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .

HY-109144

Enavogliflozin DWP-16001	SGLT	Metabolic Disease
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .

HY-13413

Tofogliflozin (hydrate) 4 Publications Verification CSG-452 hydrate	SGLT Reactive Oxygen Species	Metabolic Disease
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.9 nM and K_i values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse *SGLT2* . Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells .

HY-15461R

Ertugliflozin (Standard)	SGLT	Metabolic Disease
Ertugliflozin (Standard) is the analytical standard of Ertugliflozin. This product is intended for research and analytical applications. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-15461S

Ertugliflozin-d5 PF-04971729-d₅	SGLT	Metabolic Disease
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin[1]. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[2]. Has the potential for the treatment of type 2 diabetes mellitus[3].

HY-15461S1

Ertugliflozin-d9 PF-04971729-d₉	SGLT Isotope-Labeled Compounds	Metabolic Disease
Ertugliflozin-d₉ is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-101782

HSK0935	SGLT	Metabolic Disease
HSK0935 is a potent, highly selective and orally available *SGLT2* inhibitor with an IC₅₀ of 1.3 nM. Antihyperglycemic activities .

HY-153113

Rongliflozin DJT1116PG	SGLT	Endocrinology
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-14894A

Ipragliflozin L-Proline 5+ Cited Publications	SGLT	Metabolic Disease
Ipragliflozin (L-Proline) is a highly potent and selective *SGLT2* inhibitor with an IC₅₀ of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.

HY-N2189

Swertisin 1 Publications Verification	Adenosine Receptor HBV SGLT	Infection Neurological Disease Inflammation/Immunology
Swertisin is an oral adenosine A1 receptor antagonist and an *SGLT2* inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice .

HY-10451

Canagliflozin 30+ Cited Publications JNJ 28431754	SGLT	Metabolic Disease Cancer
Canagliflozin (JNJ 28431754) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

HY-I0383

Canagliflozin hemihydrate 30+ Cited Publications JNJ 28431754 hemihydrate	SGLT	Metabolic Disease Cancer
Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-12608

TA-1887 JNJ-39933673	SGLT	Metabolic Disease
TA-1887 (JNJ-39933673) is a highly potent, selective and orally active *SGLT2* inhibitor (IC₅₀: 1.4 nM) with antihyperglycemic effects. TA-1887 can be used in the research of diabetes .

HY-123797

KGA-2727 1 Publications Verification	SGLT	Metabolic Disease
KGA-2727 is a first selective, high-affinity and orally active *SGLT1* inhibitor with K_is of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (K_i for SGLT2/K_i for *SGLT1*) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy .

HY-14810

Atigliflozin AVE-2268	SGLT	Metabolic Disease
Atigliflozin (AVE-2268) is an orally active and selective *SGLT-2* inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .

HY-10449A

Luseogliflozin hydrate TS 071 hydrate	SGLT	Metabolic Disease
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .

HY-109018B

Velagliflozin proline hydrate 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-106158

T-1095	SGLT	Metabolic Disease
T-1095 is a selective and orally active Na ⁺-glucose cotransporter (SGLT) inhibitor with IC₅₀s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research .

HY-125327

YM-543	Others	Metabolic Disease
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.

HY-10451R

Canagliflozin (Standard)	SGLT	Metabolic Disease Cancer
Canagliflozin (Standard) is the analytical standard of Canagliflozin. This product is intended for research and analytical applications. Canagliflozin (JNJ 28431754) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

HY-10451S2

Canagliflozin-d6 JNJ 28431754-d₆	SGLT	Metabolic Disease
Canagliflozin-d₆ is the deuterium labeled Canagliflozin[1]. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively[2].

HY-10450

Dapagliflozin 35+ Cited Publications BMS-512148	SGLT	Metabolic Disease Cancer
Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-101122

LX2761	SGLT	Metabolic Disease
LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and *SGLT2* in vitro with IC₅₀s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract .

HY-12611

Sergliflozin etabonate GW-869682X	SGLT	Metabolic Disease
Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .

HY-17638

Mizagliflozin 3 Publications Verification DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base	SGLT	Metabolic Disease
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective *SGLT1* inhibitor, with a K_i of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .

HY-125156

Dapagliflozin-3-O-β-D-glucuronide BMS-801576	Endogenous Metabolite	Metabolic Disease
Dapagliflozin-3-O-β-D-glucuronide (BMS-801576) is the metabolite of Dapagliflozin (HY-10450), and is formed in the liver and kidney by uridine diphosphate glucuronosyltransferase-1A9 (UGT1A9). Dapagliflozin is a selective inhibitor for *SGLT2*, that can be used to improve glycemic control and attenuate type 2 diabetes .

HY-10450R

Dapagliflozin (Standard)	SGLT	Metabolic Disease Cancer
Dapagliflozin (Standard) is the analytical standard of Dapagliflozin. This product is intended for research and analytical applications. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury .

HY-117010

Kushenol K	Cytochrome P450 HSV SGLT	Infection Metabolic Disease
Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens. Kushenol K is a cytochrome P-450 3A4 (CYP3A4) inhibitor with a K_i value of 1.35 μM . Kushenol K shows weak antiviral activity against HSV-2 (EC₅₀ of 147 μM) . Kushenol K also inhibits the activity of *SGLT1* and *SGLT2* .

HY-14945

Remogliflozin etabonate GSK189075	SGLT	Metabolic Disease
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .

HY-N0142

Phloretin 15+ Cited Publications NSC 407292; RJC 02792	SGLT Endogenous Metabolite GLUT	Metabolic Disease Cancer
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-10450A

Dapagliflozin ((2S)-1,2-propanediol, hydrate) 35+ Cited Publications BMS-512148 (2S)-1,2-propanediol, hydrate	SGLT	Metabolic Disease Cancer
Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2189

Swertisin 1 Publications Verification	Structural Classification Iridaceae Classification of Application Fields Flavones Source classification Metabolic Disease Plants Iris tectorum Maxim. Flavonoids other families Phenols Polyphenols Inflammation/Immunology Disease Research Fields	Adenosine Receptor HBV SGLT
Swertisin is an oral adenosine A1 receptor antagonist and an *SGLT2* inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice .

HY-N0142

Phloretin Maximum Cited Publications 16 Publications Verification NSC 407292; RJC 02792	Structural Classification Classification of Application Fields Source classification Rosaceae Plants Dihydrochalcones Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms Malus pumila Mill. Phenols Polyphenols Disease Research Fields Cancer	SGLT Endogenous Metabolite GLUT
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .

HY-117010

Kushenol K	Flavanonols Structural Classification Flavonoids Classification of Application Fields Leguminosae Source classification Phenols Polyphenols Metabolic Disease Plants Sophora flavescens Aiton Disease Research Fields	Cytochrome P450 HSV SGLT
Kushenol K, a flavonoid antioxidant isolated from the roots of Sophora flavescens. Kushenol K is a cytochrome P-450 3A4 (CYP3A4) inhibitor with a K_i value of 1.35 μM . Kushenol K shows weak antiviral activity against HSV-2 (EC₅₀ of 147 μM) . Kushenol K also inhibits the activity of *SGLT1* and *SGLT2* .

HY-N0142R

Phloretin (Standard) NSC 407292 (Standard); RJC 02792 (Standard)	Structural Classification Human Gut Microbiota Metabolites Flavonoids Classification of Application Fields Source classification Malus pumila Mill. Rosaceae Phenols Plants Endogenous metabolite Disease Research Fields Cancer	SGLT Endogenous Metabolite GLUT
Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC₅₀values of 49 μM and 61 μM, respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA)?and allergic airway inflammation .

Cat. No.	Product Name	Chemical Structure

HY-10451S

Canagliflozin-d4
Canagliflozin-d₄ is a deuterium labeled Canagliflozin. Canagliflozin is a selective SGLT2 inhibitor[1].

HY-10450S

Dapagliflozin-d5
Dapagliflozin-d₅ is a deuterium labeled Dapagliflozin. Dapagliflozin is a competitive SGLT2 inhibitor[1].

HY-15409S

Empagliflozin-d4
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2[1].

HY-15461S

Ertugliflozin-d5
Ertugliflozin-d₅ is the deuterium labeled Ertugliflozin[1]. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2[2]. Has the potential for the treatment of type 2 diabetes mellitus[3].

HY-15461S1

Ertugliflozin-d9
Ertugliflozin-d₉ is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC₅₀ of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .

HY-10451S2

Canagliflozin-d6
Canagliflozin-d₆ is the deuterium labeled Canagliflozin[1]. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SGLT2 inhibitor

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products